U.S., April 22 -- ClinicalTrials.gov registry received information related to the study (NCT07541287) titled 'A Phase 2 Study of JADE101 in Participants With Immunoglobulin A Nephropathy' on April 14.
Brief Summary: This open-label Phase 2 study will characterize the safety and efficacy of JADE101 in participants with IgA nephropathy, and the results will contribute to the overall clinical characterization of JADE101 in this patient population.
Study Start Date: May, 2026
Study Type: INTERVENTIONAL
Condition:
IgA Nephropathy
Intervention:
DRUG: JADE101
JADE101 is supplied as sterile solution to be administered by SC injection
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Jade Biosciences, Inc.
Published by HT Digital Content Se...